Update On Synergy Pharmaceuticals (NASDAQ: SGYP): Reiterating Buy Rating With Revised Price Target=$8.

SGYP, AGN

Shares of Synergy Pharmaceuticals (NASDAQ: [[SGYP]]) have disappointed investors since the FDA approval of Trulance (Plecanatide) for the treatment of chronic idiopathic constipation, CIC. However, we see some signs of the reversal of downward trend. The pullback in the shares is not surprising a...

Shares of Synergy Pharmaceuticals (NASDAQ: [[SGYP]]) have disappointed investors since the FDA approval of Trulance (Plecanatide) for the treatment of chronic idiopathic constipation, CIC. However, we see some signs of the reversal of downward trend. The pullback in the shares is not surprising a...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics